Moasser MM - Search Results

1

A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. Huron DR, et al. Among authors: moasser mm. Clin Cancer Res. 2003 Apr;9(4):1267-73. Clin Cancer Res. 2003. PMID: 12684394

2

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.

Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. Moasser MM, et al. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1369-74. doi: 10.1073/pnas.95.4.1369. Proc Natl Acad Sci U S A. 1998. PMID: 9465021 Free PMC article.

3

Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.

Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Moasser MM, et al. Cancer Res. 1999 Dec 15;59(24):6145-52. Cancer Res. 1999. PMID: 10626805

4

Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.

Münster PN, Srethapakdi M, Moasser MM, Rosen N. Münster PN, et al. Among authors: moasser mm. Cancer Res. 2001 Apr 1;61(7):2945-52. Cancer Res. 2001. PMID: 11306472

5

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Moasser MM, Basso A, Averbuch SD, Rosen N. Moasser MM, et al. Cancer Res. 2001 Oct 1;61(19):7184-8. Cancer Res. 2001. PMID: 11585753

6

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Clin Cancer Res. 2001 Dec;7(12):3934-41. Clin Cancer Res. 2001. PMID: 11751485 Clinical Trial.

7

The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.

Moasser MM, Rosen N. Moasser MM, et al. Breast Cancer Res Treat. 2002 May;73(2):135-44. doi: 10.1023/a:1015209123900. Breast Cancer Res Treat. 2002. PMID: 12088116

8

Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.

Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI. Sepp-Lorenzino L, et al. Among authors: moasser mm. Prostate Cancer Prostatic Dis. 2001;4(1):33-43. doi: 10.1038/sj.pcan.4500491. Prostate Cancer Prostatic Dis. 2001. PMID: 12497061

9

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

She QB, Solit D, Basso A, Moasser MM. She QB, et al. Among authors: moasser mm. Clin Cancer Res. 2003 Oct 1;9(12):4340-6. Clin Cancer Res. 2003. PMID: 14555504

10

S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors.

Mizenina OA, Moasser MM. Mizenina OA, et al. Among authors: moasser mm. Cell Cycle. 2004 Jun;3(6):796-803. Epub 2004 Jun 5. Cell Cycle. 2004. PMID: 15136770

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page